Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

19.73 -0.37 (-1.84%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting

November 03, 2022

Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH)

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results

October 31, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Where Apellis Pharmaceuticals Stands With Analysts ↗

September 08, 2022

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:

Via Benzinga

7 Analysts Have This to Say About Apellis Pharmaceuticals ↗

October 18, 2022

Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

October 04, 2022

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Via MarketBeat

Topics Stocks

Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today ↗

October 03, 2022

Both companies presented data at the American Academy of Ophthalmology meeting.

Via Investor's Business Daily

Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years ↗

August 24, 2022

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

August 09, 2022

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:

Via Benzinga

HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals ↗

July 19, 2022

Via Benzinga

October 04, 2022

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...

Via Benzinga

Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session ↗

October 03, 2022

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Via Benzinga

Investigator Says Apellis' Lead Product Shows 'First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth' ↗

October 03, 2022

Via Benzinga

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

September 30, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

September 30, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

September 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗

September 08, 2022

Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the...

Via Benzinga

Moderna To $165? Plus This Analyst Cuts PT On FedEx ↗

September 08, 2022

Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to...

Via Benzinga

Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗

August 25, 2022

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.

Via Benzinga

Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday ↗

August 25, 2022

U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study ↗

August 24, 2022

Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in...

Via Benzinga

7 Cheap Biotech Stocks to Buy Now ↗

August 03, 2022

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

Via InvestorPlace

Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

July 27, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary ↗

July 19, 2022

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness...

Via Benzinga

Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher ↗

July 19, 2022

U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.

Via Benzinga

July 20, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 19, 2022

Via Benzinga

Dow Climbs Over 500 Points as Upbeat Earnings Roll In ↗

July 19, 2022

The Dow Jones Industrial Average is up 510 points midday, as the newest string of earnings reports shows companies working through the current economic pressures.

Via Talk Markets

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

All News about Apellis Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today